Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab combination study in multiple myeloma
NL-OMON53994Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of talquetamab in multiple myeloma (MM) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events as a measure of safety and tolerability, Number of participants with adverse events by severity and 2 more. Started Mar 2022; status: recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON53994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53994.